Asymchem Laboratories (Tianjin) Co., Ltd.

XSEC:002821 Stock Report

Market Cap: CN¥26.2b

Asymchem Laboratories (Tianjin) Valuation

Is 2821 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2821 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002821 (CN¥76.51) is trading below our estimate of fair value (CN¥129.37)

Significantly Below Fair Value: 002821 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2821?

Other financial metrics that can be useful for relative valuation.

2821 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.5x
Enterprise Value/EBITDA8.4x
PEG Ratio3x

Price to Earnings Ratio vs Peers

How does 2821's PE Ratio compare to its peers?

The above table shows the PE ratio for 2821 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average51.1x
600521 Zhejiang Huahai Pharmaceutical
27.4x21.2%CN¥25.1b
002262 Jiangsu Nhwa Pharmaceutical
22.6x19.5%CN¥23.9b
300573 Shenyang Xingqi PharmaceuticalLtd
126.3x35.2%CN¥34.0b
600329 Tianjin Pharmaceutical Da Ren Tang Group
27.9x19.2%CN¥24.0b
002821 Asymchem Laboratories (Tianjin)
13.8x4.6%CN¥26.2b

Price-To-Earnings vs Peers: 002821 is good value based on its Price-To-Earnings Ratio (13.8x) compared to the peer average (51.1x).


Price to Earnings Ratio vs Industry

How does 2821's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.7%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.7%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 002821 is good value based on its Price-To-Earnings Ratio (13.8x) compared to the CN Pharmaceuticals industry average (27.6x).


Price to Earnings Ratio vs Fair Ratio

What is 2821's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2821 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.8x
Fair PE Ratio23.5x

Price-To-Earnings vs Fair Ratio: 002821 is good value based on its Price-To-Earnings Ratio (13.8x) compared to the estimated Fair Price-To-Earnings Ratio (23.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2821 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥76.51
CN¥99.43
+30.0%
20.9%CN¥145.00CN¥61.00n/a11
Jun ’25CN¥76.69
CN¥99.43
+29.6%
20.9%CN¥145.00CN¥61.00n/a11
May ’25CN¥82.65
CN¥99.43
+20.3%
20.9%CN¥145.00CN¥61.00n/a11
Apr ’25CN¥87.00
CN¥127.74
+46.8%
25.5%CN¥184.00CN¥85.00n/a10
Mar ’25CN¥102.24
CN¥152.54
+49.2%
23.4%CN¥197.56CN¥91.40n/a9
Feb ’25CN¥90.72
CN¥159.52
+75.8%
22.7%CN¥197.56CN¥91.40n/a9
Jan ’25CN¥116.10
CN¥166.73
+43.6%
18.6%CN¥197.56CN¥106.57n/a9
Dec ’24CN¥141.00
CN¥170.73
+21.1%
17.4%CN¥197.56CN¥106.57n/a9
Nov ’24CN¥146.21
CN¥170.03
+16.3%
17.6%CN¥197.56CN¥106.25n/a9
Oct ’24CN¥151.70
CN¥155.20
+2.3%
21.5%CN¥200.30CN¥100.13n/a9
Sep ’24CN¥131.67
CN¥155.86
+18.4%
21.6%CN¥200.30CN¥100.13n/a9
Aug ’24CN¥125.79
CN¥159.22
+26.6%
23.2%CN¥196.74CN¥100.13n/a9
Jul ’24CN¥117.86
CN¥167.63
+42.2%
29.8%CN¥268.60CN¥100.13n/a9
Jun ’24CN¥136.02
CN¥175.30
+28.9%
27.2%CN¥268.60CN¥100.13CN¥76.698
May ’24CN¥126.45
CN¥175.97
+39.2%
26.7%CN¥268.60CN¥100.13CN¥82.658
Apr ’24CN¥133.33
CN¥188.15
+41.1%
28.4%CN¥288.10CN¥100.13CN¥87.007
Mar ’24CN¥143.76
CN¥195.53
+36.0%
30.6%CN¥323.20CN¥117.42CN¥102.247
Feb ’24CN¥165.96
CN¥195.03
+17.5%
31.4%CN¥323.20CN¥109.49CN¥90.727
Jan ’24CN¥148.00
CN¥195.03
+31.8%
31.4%CN¥323.20CN¥109.49CN¥116.107
Dec ’23CN¥137.48
CN¥195.03
+41.9%
31.4%CN¥323.20CN¥109.49CN¥141.007
Nov ’23CN¥150.17
CN¥209.29
+39.4%
26.0%CN¥323.20CN¥145.70CN¥146.216
Oct ’23CN¥138.70
CN¥232.91
+67.9%
22.6%CN¥311.00CN¥165.00CN¥151.706
Sep ’23CN¥170.32
CN¥248.78
+46.1%
25.3%CN¥345.10CN¥165.00CN¥131.675
Aug ’23CN¥163.86
CN¥286.13
+74.6%
19.3%CN¥353.84CN¥199.86CN¥125.794
Jul ’23CN¥202.88
CN¥285.67
+40.8%
17.3%CN¥353.84CN¥199.86CN¥117.865
Jun ’23CN¥183.26
CN¥292.06
+59.4%
16.2%CN¥353.84CN¥199.86CN¥136.026

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.